Wednesday, April 2, 2014

Would-be Lilly foe wins U.S. panel backing for inhaled insulin

Reported at The IBJ -
"MannKind Corp.’s inhaled diabetes treatment won the backing of a panel of U.S. regulatory advisers, boosting the company’s long-running effort to get its first product on the market. Shares more than doubled in extended trading Tuesday after the panel’s recommendation.

Advisers to the Food and Drug Administration voted 13-1 and 14-0 that the drug, Afrezza, should be approved for Type 1 and Type 2 diabetes, respectively. The FDA doesn’t have to follow the panel’s recommendation. FDA staff raised concerns in a report March 28 that the drug may affect lung function and about missing data from a study on Type 1 diabetes patients."

Continue Reading »

No comments:

Sale of 26 Marsh stores approved by bankruptcy court, remaining 18 stores to close

From Fox59 On Tuesday, FOX59 learned two companies won the bidding war: Topvalco and Generative Growth II. Topvalco is a Kroger subsidiary...